Enzymatic degradation and immunogenic properties of derivatized dextrans.

Dextran T40 was modified with carboxylic, benzylamide and benzylamine-sulphonated groups (samples 1-10). The polymers were incubated with dextranase and the decrease of molecular weight was determined by high performance size exclusion chromatography. It was shown that the higher the substitution of dextrans, the lower their degradability. Modification of dextran with benzylamine and benzylamine-sulphonated groups appeared to hinder the formation of the enzyme-substrate complex more than the same quantity of carboxylic groups. The immunogenicity of one of the modified dextrans, containing 54% of carboxylic groups and 19.5% of benzylamine-sulphonated groups, was determined after subcutaneous and intravenous administration into Balb/c mice. The antibody titre was very low even if administered in complete Freund's adjuvant and did not depend on the injected dose. On the average, the titres of antibodies were lower by five orders of magnitude compared to bovine gamma globulin.

[1]  J. Lloyd Explorations in cell biology and pharmacology using synthetic polymers , 1989 .

[2]  M. Kazatchkine,et al.  Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans. , 1987, Biomaterials.

[3]  F. Arranz,et al.  Water‐insoluble dextrans by grafting, 2. Reaction of dextrans with n‐alkyl chloroformates. Chemical and enzymatic hydrolysis , 1985 .

[4]  M. Kazatchkine,et al.  Anticomplementary activity of dextran derivatives. , 1985, Biomaterials.

[5]  C. Fernández,et al.  A Synergistic Polyclonal Response to Dextran Sulphate and Lipopolysaccharide , 1982, Scandinavian journal of immunology.

[6]  E. Engvall,et al.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. , 1972, Journal of immunology.

[7]  Martin Weigert,et al.  Genetics of the Antibody Response to Dextran in Mice , 1972, Science.

[8]  M. Mauzac,et al.  Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization. , 1984, Biomaterials.

[9]  R. Ammon [The occurrence of dextranase in human tissue]. , 1963, Enzymologia.

[10]  S. Vansteenkiste,et al.  Some Aspects of the Application of Dextran in Prodrug Design , 1988 .

[11]  L. Hood,et al.  Combining site specificities of mouse hybridoma antibodies to dextran B1355S , 1983, The Journal of experimental medicine.

[12]  A. Meijer,et al.  THE ACTIVITY OF GLUCOSE-6-PHOSPHATASE, ADENOSINE TRIPHOSPHATASE, SUCCINIC DEHYDROGENASE, AND ACID PHOSPHATASE AFTER DEXTRAN OF POLYVINYLPYRROLIDONE UPTAKE BY LIVER IN VIVO. , 1963, Biochemical pharmacology.

[13]  F. Seela,et al.  Polymer‐linked acycloguanosine , 1984 .

[14]  O. Mäkelä,et al.  Immunogenic Properties of α(1 → 6) Dextran, Its Protein Conjugates, and Conjugates of Its Breakdown Products in Mice , 1984, Scandinavian journal of immunology.

[15]  A. Fischer,et al.  Anticoagulant activity of dextran derivatives. Part II: Mechanism of thrombin inactivation. , 1985, Biomaterials.

[16]  M. Kazatchkine,et al.  Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. , 1988, Biomaterials.

[17]  E. Hehre,et al.  DEGRADATION OF DEXTRANS BY ENZYMES OF INTESTINAL BACTERIA , 1956, Journal of bacteriology.